Envision Series 2021 — Virtual Screening, Orion® as a Managed Service, Lead Optimization,  and Antibody Engineering

Posted by OpenEye Scientific on September 28, 2021 — Topics: Envision
Envision 2021_v07-tiny

Registration is now open.

Join us for the OpenEye Envision Series, a program of four online events covering specific industry topics, occurring on four different days, in the month of October.

Hear from both OpenEye and industry speakers focusing on specific topics in-depth for each session, including a 10-15 minute Q&A and discussion period following the presentations.

There will be 3-5 talks per session – which will occur in the morning U.S. & Americas time / mid-late afternoon Europe time / late evening Asia time.

Start and end times across timezones are as follows:

  • 11 p.m.– 2 a.m. Japan Standard Time (JST)
  • 7:30 – 10:30 p.m. India Standard Time (IST)
  • 4 – 7 p.m. Central European Summer Time (CEST)
  • 3 – 6 p.m. British Summer Time (BST)
  • 10 a.m.– 1 p.m. U.S. Eastern Daylight Time (EDT)
  • 9 a.m.– 12 Noon U.S. Central Daylight Time (CDT)
  • 7 – 10 a.m. U.S. Pacific Daylight Time (PDT)

Check back later for final session conclusion times. Featured topics during the Envision series are below:

Virtual Screening at the Giga Scale (Available On-Demand)

Tuesday, October 12, 2021


Learn about the latest work in Giga Scale, searching billions of molecules in Orion, and hear from guest Speaker Gregory Prikler of Mcule.

  • Giga Screening: Finding Molecule Straws in a Haystack - Mark McGann, Senior Principal Scientific Developer, OpenEye Scientific
  • Advanced Techniques for Screening Billions - Mark McGann, Senior Principal Scientific Developer, OpenEye Scientific
  • Gigadock™ Demo in Orion - Gunther Stahl, Senior Application Scientist, OpenEye Scientific
  • Small Molecular Compound Selection and Sourcing - Greg Prikler, Director of Business Development, Mcule

Register Now For This Event


Using Orion® as a Managed Service to Develop World-Class Drug Discovery Scientific Methods

Thursday, October 21, 2021


Learn about how your own managed service installation of Orion can accelerate your company’s ability to innovate in scientific computation and rapidly deliver key results to impact ongoing projects.

  • Orion as a Managed Service: A Powerful Platform for Scientific Development and Integration - Matt Geballe, VP, Product, OpenEye Scientific
  • Integrating Orion in Big Pharma for Fun & Profit - Scott Johnson, Senior Principal Scientist, Bristol-Meyers Squibb
  • How to Exploit Orion as a Scientific Platform: Permeability as a Case Study in Large Scale Floe Development - David LeBard, Senior Scientific Software Developer, OpenEye Scientific

Register Now For This Event


Engaging Cutting-Edge Lead Optimization Tools in Your Drug Development Process

Tuesday, October 26, 2021


During the lead optimization phase of drug development, there are many opportunities for computational approaches to make a positive impact. This retrospective presentation highlights some of the computational tools developed by OpenEye Scientific Software to support a structure-enabled lead optimization campaign using the Tyk2 kinase as an example.

  • Presentation & Overview of Lead Optimization in Drug Development - Steve Muchmore, Head of Orion Services, OpenEye Scientific
  • Structure Preparation - Gunther Stahl, Senior Application Scientist, OpenEye Scientific
  • Idea and Focused Library Generation - David Hamilton, Application Scientist, OpenEye Scientific
  • Docking and Scoring and Posing - Scott Brown, Associate Director, Orion Services, OpenEye Scientific
  • Other Binding Energy Evaluation - Varsha Jain, Application Scientist, OpenEye Scientific
  • Dynamics Based Scoring - Christopher Bayly, Head of Molecular Dynamics, OpenEye Scientific

Register Now For This Event


Applying the Latest High-Throughput Technologies to Your Antibody Drug Discovery Pipeline

Thursday, October 28, 2021


Hear from Andrew Bradbury, Founder and CSO of Specifica, M. Frank Erasmus, Head of Bioinformatics of Specifica, as well as Guest Speaker Sai Reddy, Associate Professor from ETH Zurich as they discuss their latest work and developments in Antibody Engineering.

  • Drug-like Antibodies Directly from Specifica’s Generation 3 Discovery Platform - Andrew Bradbury, MD, PhD, Founder & CSO, Specifica, Inc.
  • Antibody Discovery in the Cloud  - M. Frank Erasmus, MS, PhD, Head of Bioinformatics, Specifica, Inc.
  • Predictive Profiling of Sars-CoV-2 Variants by Deep Mutational Learning -  Sai Reddy, Associate Professor of Systems and Synthetic Immunology in the Department of Biosystems Science & Engineering at ETH Zurich

In Partnership with Specifica, Inc.


Register Now For This Event


Topic: Envision